Researchers at the Indian Institute of Technology Jodhpur (IIT Jodhpur) in Rajasthan say gene-activity changes seen in people during a meditation programme overlap with the molecular signatures of 438 pharmaceutical compounds, many of which act on brain chemical messengers such as GABA, glutamate, dopamine and serotonin. The institute announced the findings on 18 November 2026 in a release issued through the Press Information Bureau in Jaipur. The researchers stress that the work is exploratory and does not show that meditation works like, or can replace, medicines.

The paper, titled "Meditation as a bioactive intervention: evidence of translational potential via Connectivity Mapping and TMS neurophysiology", was published in the peer-reviewed journal Frontiers in Human Neuroscience on 9 November 2026, according to the release and the journal's registered publication record.

Who did the study?

The work was led by Prof. Mitali Mukerji of IIT Jodhpur's Department of Bioscience and Bioengineering, who works in Ayurgenomics, with her PhD student Aditi Joshi. They collaborated with Dr Vignesh Muralidharan, an AI and cognitive neuroscience faculty member in the same department, and Deep Patel, a former BTech student of the institute's computer science department who is now at Yale University, the release said. An earlier version of the work by the same four authors was posted as a preprint on bioRxiv in December 2025.

How did the researchers reach the 438-drug figure?

The team did not recruit new volunteers. It reanalysed a publicly available gene-expression dataset from 106 people who took part in an Inner Engineering meditation retreat, covering 389 biological profiles taken at four points: before the programme, after an eight-week preparatory phase, eight days after the retreat, and three months later.

Using a computational method called the Connectivity Map (CMap), they compared the meditation-linked changes in gene activity with the signatures that thousands of drugs produce. This turned up links with 438 unique compounds. The strongest pathway signal, the release said, was the neuroactive ligand–receptor interaction pathway, which is involved in communication between nerve cells.

The researchers then compared these results with published studies that used transcranial magnetic stimulation (TMS), a non-invasive way of measuring brain activity, to test how drugs change the balance between excitation and inhibition in the brain. That meta-analysis covered 75 drugs, 55 drug classes and 21 measures of brain activity.

What did they find at different stages?

According to the release, the links changed over time. The preparatory phase was associated with GABA- and dopamine-related pathways; the intensive retreat phase with GABA and calcium-channel mechanisms along with glutamate, dopamine and serotonin; and the follow-up phase with a different mix of GABA, dopamine and serotonin signatures. Among specific drug classes, the team noted connections involving zolpidem, a sleep medicine that acts on GABA receptors, and drugs affecting glutamate and acetylcholine signalling. Responses also varied between individuals.

"Our findings reveal interesting connections between meditation-associated gene expression patterns and pathways targeted by several neuroactive drugs," Prof. Mukerji said in the release, adding that the work opens up the possibility of studying meditation through both molecular biology and brain physiology.

What are the limitations?

The researchers themselves list several. The study relied on an existing dataset, had no control group of people who did not meditate, and did not measure participants' brain activity with TMS directly. The gene-expression data came from blood samples, which may not reflect changes inside the brain. They say further experiments are needed to validate the findings, and that guidance and supervision matter when meditation is used alongside clinical treatment.

What comes next?

The team has proposed future studies that combine molecular analysis with TMS, electromyography (EMG) and electroencephalography (EEG) to measure brain activity directly before and after meditation, to test whether the molecular changes are matched by measurable changes in brain excitation, inhibition and plasticity.

Photo source · Vyacheslav Argenberg, CC BY 4.0